STRYKER CORP — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Stryker reported Q3 2026 net sales of $6.5B (+7.7% organic), with MedSurg/Neuro at $3.7B (+9.1% organic) and Orthopaedics at $2.9B (+5.9% organic). Adjusted operating margin expanded 60 bps to 26.2%; adjusted EPS grew 10.3% to $3.52 despite reported EPS declining 11.7% to $1.96 (from $293M goodwill impairment). The Board approved a $3.0B increase to the share repurchase program; $1.0B was repurchased in Q3. 2026 guidance updated to 6.5–7.0% organic growth and adjusted EPS of $14.80–$14.90.
Why this rating
Solid organic growth and margin expansion offset by goodwill write-down; buyback authorization is routine capital allocation. Modest relative to $144B market cap.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.